You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

244 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Apr 2024
If you got a letter from ColonCancerCheck with an abnormal fecal immunochemical test (FIT) result, the information on this page can help you...
Guidelines and Advice
May 2019
Regimen
Intent: Palliative
Apr 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Apr 2024
Document
Document
Document
Document
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Sep 2024

Pages